Construction and biological characterization of an interleukin-12 fusion protein (Flexi-12): delivery to acute myeloid leukemic blasts using adeno-associated virus

Human Gene Therapy
R AndersonH G Prentice

Abstract

Interleukin-12 (IL-12) is a cytokine that exhibits pleiotropic effects on lymphocytes and natural killer cells and has been shown to have promise for the immunotherapy of cancer. The combination of the immune costimulatory molecule B7.1 and IL-12 has been shown to be synergistic for T cell activation. By transfecting tumor cells with both IL-12 and B7.1 cDNAs, it may be possible to use these modified targets as vaccines. A major obstacle in designing a vector to deliver these genes results from the structure of IL-12. Functional IL-12 is a heterodimer composed of two distinct subunits that are encoded by separate genes on different chromosomes. Production of functional IL-12 requires the coordinated expression of both genes. This presents several problems in vectors, particularly those in which additional genes, either a co-stimulatory gene or a selectable marker, are inserted. Therefore, we have constructed a single cDNA that encodes a single-chain protein, called Flexi-12, which retains all of the biological characteristics of recombinant IL-12 (rIL-12). The monomeric polypeptide Flexi-12 is able to induce the proliferation of phytohemagglutinin (PHA) blasts, induce PHA blasts to secrete interferon-gamma (IFN-gamma) and addit...Continue Reading

References

Sep 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·A S SternR Chizzonite
Sep 12, 1989·Nucleic Acids Research·H ForsterS Leong
Oct 11, 1994·Proceedings of the National Academy of Sciences of the United States of America·J L MillerA W Nienhuis
Oct 1, 1995·Molecular and Cellular Biology·T L MurphyK M Murphy
Aug 1, 1995·Proceedings of the National Academy of Sciences of the United States of America·C M BaconJ J O'Shea
Mar 17, 1995·The Journal of Biological Chemistry·J J ZouU Gubler
Jul 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·R T GazzinelliA Sher
Sep 1, 1993·European Journal of Immunology·F MattnerT Germann
Oct 1, 1993·The Journal of Experimental Medicine·M J BrundaM K Gately

❮ Previous
Next ❯

Citations

Nov 6, 2003·Journal of Virological Methods·Alistair WhitewayRobert Anderson
Oct 31, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Li ChenSavio L C Woo
Sep 13, 2002·Immunology·Joanna Galea-Lauri
Jul 3, 2008·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Jianyun LiuCarole L Cramer
Apr 18, 2000·Journal of Clinical Pathology·M W Lowdell, M B Koh
Feb 25, 2005·Blood·Karin C StraathofCliona M Rooney
Apr 27, 2011·Cancer Immunology, Immunotherapy : CII·Evelien L J SmitsBarbara-Ann Guinn
Dec 19, 2003·Expert Opinion on Biological Therapy·Selvarangan Ponnazhagan
Mar 1, 2006·Expert Opinion on Biological Therapy·Aaron E Foster, Cliona M Rooney
Mar 3, 2004·Biotechnology and Bioengineering·Abel Gutiérrez-OrtegaMiguel Angel Gómez-Lim
Aug 19, 2000·Molecular Therapy : the Journal of the American Society of Gene Therapy·A MaheshwariS W Kim
May 23, 2001·Leukemia·V F Van TendelooZ N Berneman
May 29, 2003·British Journal of Cancer·K E SiapatiS L Hart
Mar 18, 2009·The Oncologist·Evelien L J M SmitsViggo F I Van Tendeloo
Dec 23, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sang-Jun HaYoung-Chul Sung
Feb 20, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ling ZhangSteven A Rosenberg
Oct 20, 1999·Methods : a Companion to Methods in Enzymology·M Rodolfo, M P Colombo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.